HUP0303900A2 - Az arteminnek, a GDNF ligandum család egy tagjának új alkalmazása - Google Patents

Az arteminnek, a GDNF ligandum család egy tagjának új alkalmazása

Info

Publication number
HUP0303900A2
HUP0303900A2 HU0303900A HUP0303900A HUP0303900A2 HU P0303900 A2 HUP0303900 A2 HU P0303900A2 HU 0303900 A HU0303900 A HU 0303900A HU P0303900 A HUP0303900 A HU P0303900A HU P0303900 A2 HUP0303900 A2 HU P0303900A2
Authority
HU
Hungary
Prior art keywords
artemin
new use
ligand family
gdnf ligand
mammals
Prior art date
Application number
HU0303900A
Other languages
English (en)
Inventor
Heidi S. Phillips
David L. Shelton
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HUP0303900A2 publication Critical patent/HUP0303900A2/hu
Publication of HUP0303900A3 publication Critical patent/HUP0303900A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány artemin alkalmazásával foglalkozik idegsejtsérülések ésidegsejtsérülésekkel társult változások megelőzésére vagy kezelésére.Pontosabban a találmány eljárást nyújt neuronok védelmére emlősökben asérülés által indukált patológiás változásoktól, és eljárást nyújtneuronális károsodások kezelésére emlősökben, artemin vagy valamelyartemin agonista bevezetésével. Ó
HU0303900A 2000-12-22 2001-12-19 New use of artemin, a member of the gdnf ligand family HUP0303900A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25760100P 2000-12-22 2000-12-22
PCT/US2001/050112 WO2002051433A2 (en) 2000-12-22 2001-12-19 Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament

Publications (2)

Publication Number Publication Date
HUP0303900A2 true HUP0303900A2 (hu) 2004-03-01
HUP0303900A3 HUP0303900A3 (en) 2009-08-28

Family

ID=22976954

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303900A HUP0303900A3 (en) 2000-12-22 2001-12-19 New use of artemin, a member of the gdnf ligand family

Country Status (14)

Country Link
US (2) US20040242472A1 (hu)
EP (1) EP1423139A2 (hu)
JP (2) JP2005502582A (hu)
KR (2) KR20080067719A (hu)
CN (1) CN1547483A (hu)
AU (2) AU2002232785B2 (hu)
BR (1) BR0116749A (hu)
CA (1) CA2432977A1 (hu)
HU (1) HUP0303900A3 (hu)
IL (1) IL156559A0 (hu)
MX (1) MXPA03005721A (hu)
NZ (1) NZ526610A (hu)
PL (1) PL366333A1 (hu)
WO (1) WO2002051433A2 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
US8208364B2 (en) 2002-10-25 2012-06-26 Qualcomm Incorporated MIMO system with multiple spatial multiplexing modes
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EA008743B1 (ru) * 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
NZ574121A (en) * 2003-04-18 2011-06-30 Biogen Idec Inc Polyethylene glycol-conjugated gylcosylated neublastin and uses thereof for treatment of pain
BRPI0411243A (pt) 2003-06-10 2006-07-11 Nsgene As método de produzir um polipeptìdio de neublastina biologicamente ativo, ácido nucléico, vetor de expressão, composição farmacêutica, célula, linha de células de compactação, mamìfero não-humano transgênico, dispositivo de cultura de células implantável, uso do vetor, método de tratar uma doença do sistema nervoso, e, polipetìdio de neublastina
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
NZ553431A (en) * 2004-08-19 2010-04-30 Biogen Idec Inc Neublastin variants with decreased heparin binding
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
EP2142205B1 (en) * 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20140038887A1 (en) * 2011-05-05 2014-02-06 Us Government Represented By The Us Department Of Veterans Affairs Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
US10052362B2 (en) 2011-05-05 2018-08-21 Emory University Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
WO2015042580A1 (en) * 2013-09-23 2015-03-26 Biogen Idec Ma Inc. Compositions and methods for treatment of neuropathic pain
US11331480B2 (en) * 2017-04-03 2022-05-17 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
CN108733907B (zh) * 2018-05-15 2020-08-25 武汉理工大学 探索元胞自动机模型的尺度敏感性的耦合方法
CN113174342B (zh) * 2021-03-30 2023-07-07 大连工业大学 高效降解氨基甲酸乙酯的菌株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
BR9912819A (pt) * 1998-07-14 2001-05-02 Janssen Pharmaceutica Nv Fator de crescimento neurotrófico
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor

Also Published As

Publication number Publication date
EP1423139A2 (en) 2004-06-02
AU2002232785B2 (en) 2006-05-18
AU2006203454A1 (en) 2006-08-31
PL366333A1 (en) 2005-01-24
WO2002051433A2 (en) 2002-07-04
BR0116749A (pt) 2006-11-28
CN1547483A (zh) 2004-11-17
US20040242472A1 (en) 2004-12-02
JP2005502582A (ja) 2005-01-27
NZ526610A (en) 2009-08-28
KR20040067841A (ko) 2004-07-30
MXPA03005721A (es) 2004-04-21
US20050181991A1 (en) 2005-08-18
CA2432977A1 (en) 2002-07-04
AU2006203454B2 (en) 2009-05-21
KR20080067719A (ko) 2008-07-21
WO2002051433A3 (en) 2004-03-25
JP2009263360A (ja) 2009-11-12
HUP0303900A3 (en) 2009-08-28
IL156559A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
HUP0303900A2 (hu) Az arteminnek, a GDNF ligandum család egy tagjának új alkalmazása
ATE439140T1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
HK1069767A1 (en) Methods for inhibiting ocular processes
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
ID28916A (id) Pengobatan ketagihan dan perilaku yang berkaitan dengan ketagihan
CY1114445T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων
DE69732868D1 (de) Mittel gegen Juckreiz
BR9814923A (pt) Método para tratamento de doença de alzheimer
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
AU2003270166A1 (en) Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
CA2340921A1 (en) Use of taxanes to treat brain cancer
ZA200609220B (en) Method of treating dry eye disorders and uveitis
TW200503717A (en) Substituted 1,4-pyrazine derivatives
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
DE60332481D1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
BR0113266A (pt) Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
WO2003045325A3 (en) Dopaminergic stimulatory factor

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees